The combination therapy group significantly inhibited tumor progression, reduced mortality in mice, decreased the proportion of tetramer+CD8+ Tex‐term cells, and increased the proportion of tetramer+IFN‐γ−GzmB+ T and tetramer+IFN‐γ+GzmB− T cells (Figure 4F–I). The gene discussed is CD8A; the disease is neoplasm.